SHERRYWUSHERRY WU11822WU, SHERRYAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonBioinformatics & Computational BiologyExperimental TherapeuticsGynecological Oncology & Reproductive MedicineMolecular & Cellular OncologySystems BiologyMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessorKEITH ABAGGERLYKEITH A BAGGERLY8875BAGGERLY, KEITH AProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorROBERTCOLEMANROBERT COLEMAN9184COLEMAN, ROBERTProfessorSUNILAPRADEEPSUNILA PRADEEP9724PRADEEP, SUNILAInstructorLINGEGOWDA SELANEREMANGALALINGEGOWDA SELANERE MANGALA9112MANGALA, LINGEGOWDA SELANEREInstructorGEORGE ACALINGEORGE A CALIN9408CALIN, GEORGE AProfessorANIL KSOODANIL K SOOD9048SOOD, ANIL KProfessor22585855Wu SY, Sood AKCancer discoveryNew roles opined for OPCML. Cancer Discov. 2012 Feb; 2(2):115-6.Cancer Discov2012-02-01T00:00:002012New roles opined for OPCML.24018975Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AKNature communicationsTumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.Nat Commun2013-01-01T00:00:002013Tumour angiogenesis regulation by the miR-200 family.25026212Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AKCancer cellHematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.Cancer Cell2014-07-14T00:00:002014Hematogenous metastasis of ovarian cancer: rethinking mode of spread.23871637Masiero M, Sim?es FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FMCancer cellA core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.Cancer Cell2013-07-18T00:00:002013A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.24062525Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AKJournal of the National Cancer InstituteRole of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95.J Natl Cancer Inst2013-09-23T00:00:002013Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.24243015Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MACellSystematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013 Oct 24; 155(3):552-66.Cell2013-10-24T00:00:002013Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.24613353Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan VCell reportsAutocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095.Cell Rep2014-03-06T00:00:002014Autocrine effects of tumor-derived complement.24743243Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AKCancer researchNotch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.Cancer Res2014-04-17T00:00:002014Notch3 pathway alterations in ovarian cancer.24002999Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GACancer discoveryTherapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15.Cancer Discov2013-09-03T00:00:002013Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.24619206Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AKNature communications2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.Nat Commun2014-03-12T00:00:0020142'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.24755199Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AKMolecular cancer therapeuticsMetronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.Mol Cancer Ther2014-04-22T00:00:002014Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.24920658Wu SY, Lopez-Berestein G, Calin GA, Sood AKScience translational medicineRNAi therapies: drugging the undruggable. Sci Transl Med. 2014 Jun 11; 6(240):240ps7.Sci Transl Med2014-06-11T00:00:002014RNAi therapies: drugging the undruggable.24974076Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick JMolecular oncologyBRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014 Dec; 8(8):1429-40.Mol Oncol2014-06-06T00:00:002014BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.25281617Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AKMolecular cancer therapeuticsTherapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85.Mol Cancer Ther2014-10-03T00:00:002014Therapeutic silencing of KRAS using systemically delivered siRNAs.25351346Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AKNature communicationsHypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202.Nat Commun2014-10-29T00:00:002014Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.25878333Miyake T, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, Gharpure KM, Nagaraja AS, Hu W, Cho MS, Dalton HJ, Previs RA, Taylor ML, Hisamatsu T, Kang Y, Liu T, Shacham S, McCauley D, Hawke DH, Wiktorowicz JE, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchXPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res. 2015 Jul 15; 21(14):3286-97.Clin Cancer Res2015-04-15T00:00:002015XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.26081979Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein GNature communicationsThe ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351.Nat Commun2015-06-17T00:00:002015The ZNF304-integrin axis protects against anoikis in cancer.26180057Gharpure KM, Wu SY, Li C, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchNanotechnology: Future of Oncotherapy. Clin Cancer Res. 2015 Jul 15; 21(14):3121-30.Clin Cancer Res2015-07-15T00:00:002015Nanotechnology: Future of Oncotherapy.26313360Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GEOncotargetChitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77.Oncotarget2015-10-06T00:00:002015Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.26481148Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Pe?a GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AKCancer cellErythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.Cancer Cell2015-10-17T00:00:002015Erythropoietin Stimulates Tumor Growth via EphB4.26648870Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua SFrontiers in pharmacologyAdvances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015; 6:286.Front Pharmacol2015-12-01T00:00:002015Advances and Challenges of Liposome Assisted Drug Delivery.26686630Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AKCell reportsLong Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec 22; 13(11):2395-2402.Cell Rep2015-12-10T00:00:002015Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.26721492Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2016; 1402:189-197.Methods Mol Biol2016-01-01T00:00:002016Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.74Professor10Assistant Professor54Instructor1881 East RoadHouston77054-3005TXCRISTINAIVANCRISTINA IVAN11810IVAN, CRISTINAAssistant Professor1.682720.00534407327research areas8.334030.028683954coauthor of125.5038.2289360similar to1177selected publications26819345Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AKJournal of the National Cancer InstituteRole of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.J Natl Cancer Inst2016-01-26T00:00:002016Role of Increased n-acetylaspartate Levels in Cancer.27041221Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AKNature communicationsA miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016 Apr 04; 7:11169.Nat Commun2016-04-04T00:00:002016A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.27064283Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AKThe Journal of clinical investigationFAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 05 02; 126(5):1885-96.J Clin Invest2016-04-11T00:00:002016FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.Authorship 3734367Authorship 3734371Authorship 37352512Authorship 37352618Authorship 37352712Authorship 3735281Authorship 37356011Authorship 3735619Authorship 3736193Authorship 3736202Authorship 37362114Authorship 3736227Authorship 841835Authorship 842678Authorship 848874Authorship 849399Authorship 850628Authorship 851865Authorship 852151Authorship 853374Authorship 853424Authorship 853571Authorship 853750Authorship 855257Authorship 863925Authorship 864148Authorship 866331Authorship 868032Authorship 868084Frontiers in PharmacologyAdvances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 6.Advances and challenges of liposome assisted drug deliveryJournal of Clinical InvestigationFAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation. 126:1885-1896.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawalCell ReportsRole of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17:1621-1631.Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine CancersAssessment of In vivo siRNA delivery in cancer mouse models. 189-197.Assessment of In vivo siRNA delivery in cancer mouse modelsJournal of the National Cancer InstituteRole of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108.Role of Increased n-acetylaspartate Levels in CancerOncogeneHypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progressionCancer ResearchBET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Research. 76:6320-6330.BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancerFrontiers in PharmacologyThe use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Pharmacology. 4 NOV.The use of lipid-based nanocarriers for targeted pain therapiesLowering the sirna delivery barrier. 193-216.Lowering the sirna delivery barrierNature CommunicationsA miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7.A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancerOncotargetChitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 6:29161-29177.Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagyCell ReportsLong Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. 13:2395-2402.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering GlycolysisOncogeneSustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesisNature CommunicationsThe ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6.The ZNF304-integrin axis protects against anoikis in cancerClinical Cancer ResearchNanotechnology. Clinical Cancer Research. 21:3121-3130.NanotechnologyCancer CellErythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.Erythropoietin Stimulates Tumor Growth via EphB4Clinical Cancer ResearchXPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A. Clinical Cancer Research. 21:3286-3297.XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A28698296Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin LGenes & developmentPRKCI promotes immune suppression in ovarian cancer. Genes Dev. 2017 06 01; 31(11):1109-1121.Genes Dev2017-06-01T00:00:002017PRKCI promotes immune suppression in ovarian cancer.Authorship 8868243Authorship 8870407Authorship 8870794Authorship 8871031Authorship 8871818Authorship 88732915Authorship 88750712Authorship 8876382Authorship 8881902Authorship 8882626Authorship 8888181Authorship 88882519Authorship 8891072Authorship 8891218Authorship 88946610D034741Chemicals & Drugs77922170.625403RNA, Small InterferingD010051Disorders61946210.315794Ovarian NeoplasmsD009389Disorders52015470.58592Neovascularization, PathologicD008055Chemicals & Drugs3096400.727789LipidsD004337Chemicals & Drugs1663270.869616Drug CarriersAuthorship 8992671Authorship 8993271Authorship 8993881Authorship 9003844Authorship 9012002Authorship 9058836Authorship 9059012Authorship 9078432Authorship 9100484Authorship 9144646Authorship 91455515Authorship 9148383Authorship 9176975Authorship 9184985Authorship 91906213Authorship 91974913Authorship 92515810Authorship 92592920Authorship 9353452Authorship 9360413Authorship 939388619023647Wu SY, Putral LN, Liang M, Chang HI, Davies NM, McMillan NAPharmaceutical researchDevelopment of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res. 2009 Mar; 26(3):512-22.Pharm Res2008-11-21T00:00:002008Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use.19757082Wu SY, McMillan NAThe AAPS journalLipidic systems for in vivo siRNA delivery. AAPS J. 2009 Dec; 11(4):639-52.AAPS J2009-09-09T00:00:002009Lipidic systems for in vivo siRNA delivery.21315117Wu SY, Chang HI, Burgess M, McMillan NAJournal of controlled release : official journal of the Controlled Release SocietyVaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. J Control Release. 2011 Nov 07; 155(3):418-26.J Control Release2011-02-18T00:00:002011Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system.21773042Singhania A, Wu SY, McMillan NAJournal of drug deliveryEffective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. J Drug Deliv. 2011; 2011:192562.J Drug Deliv2011-06-07T00:00:002011Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration.21423261Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NAImmunology and cell biologysiRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol. 2012 Feb; 90(2):187-96.Immunol Cell Biol2011-03-22T00:00:002011siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.27803105Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang RCancer researchBET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Res. 2016 11 01; 76(21):6320-6330.Cancer Res2016-11-01T00:00:002016BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.27806300Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AKCell reportsRole of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep. 2016 11 01; 17(6):1621-1631.Cell Rep2016-11-01T00:00:002016Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.28265009Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AKMolecular cancer therapeuticsPreclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017 06; 16(6):1114-1123.Mol Cancer Ther2017-03-06T00:00:002017Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).27777972Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AKJCI insightImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016 Oct 20; 1(17):e87754.JCI Insight2016-10-20T00:00:002016Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.28223424Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodr?guez-Aguayo C, L?pez-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo MMolecular cancer therapeuticsHSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Mol Cancer Ther. 2017 05; 16(5):966-976.Mol Cancer Ther2017-02-21T00:00:002017HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer.28376174Previs RA, Armaiz-Pena GN, Ivan C, Dalton HJ, Rupaimoole R, Hansen JM, Lyons Y, Huang J, Haemmerle M, Wagner MJ, Gharpure KM, Nagaraja AS, Filant J, McGuire MH, Noh K, Dorniak PL, Linesch SL, Mangala LS, Pradeep S, Wu SY, Sood AKJournal of the National Cancer InstituteRole of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).J Natl Cancer Inst2017-07-01T00:00:002017Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.28855350Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchMacrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.Clin Cancer Res2017-08-29T00:00:002017Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.29246304Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein GMolecular therapy. Nucleic acidsTherapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids. 2017 Dec 15; 9:251-262.Mol Ther Nucleic Acids2017-07-05T00:00:002017Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.28814667Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AKJCI insightAdrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16).JCI Insight2017-08-17T00:00:002017Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.29228548Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AKOncotargetMacrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.Oncotarget2017-08-24T00:00:002017Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.29661830Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AKCancer researchSustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 06 15; 78(12):3233-3242.Cancer Res2018-04-16T00:00:002018Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.29212026Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AKCell reportsDifferential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.Cell Rep2017-12-05T00:00:002017Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.29861857Gharpure KM, Lara OD, Wen Y, Pradeep S, LaFargue C, Ivan C, Rupaimoole R, Hu W, Mangala LS, Wu SY, Nagaraja AS, Baggerly K, Sood AKOncotargetADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126.Oncotarget2018-05-18T00:00:002018ADH1B promotes mesothelial clearance and ovarian cancer infiltration.30050129Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AKNature communicationsFABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923.Nat Commun2018-07-26T00:00:002018FABP4 as a key determinant of metastatic potential of ovarian cancer.29872708Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AKNPJ precision oncologyImmune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017; 1(1):26.NPJ Precis Oncol2017-08-15T00:00:002017Immune cell profiling in cancer: molecular approaches to cell-specific identification.30305341Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AKMolecular cancer therapeuticsPRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.Mol Cancer Ther2018-10-10T00:00:002018PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.Authorship 943572830926640Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AKMolecular cancer therapeuticsGnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.Mol Cancer Ther2019-03-29T00:00:002019GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.Authorship 943905230420565Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AKMolecular cancer therapeuticsPredicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther. 2019 02; 18(2):421-436.Mol Cancer Ther2018-11-12T00:00:002018Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.Authorship 946672431056473McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AKEBioMedicinePan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine. 2019 May; 43:127-137.EBioMedicine2019-05-02T00:00:002019Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.Authorship 956152431560538Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li CBioconjugate chemistryCopper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. Bioconjug Chem. 2019 10 16; 30(10):2675-2683.Bioconjug Chem2019-09-27T00:00:002019Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention.Authorship 9909562Authorship 991033632493919Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AKNature communicationsAuthor Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2020 06 03; 11(1):2867.Nat Commun2020-06-03T00:00:002020Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.32499298Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AKMolecular cancer therapeuticsNRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735.Mol Cancer Ther2020-06-04T00:00:002020NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.Authorship 1004492533149280Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AKOncogeneThe hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.Oncogene2020-11-04T00:00:002020The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.Authorship 10111081033567287Ma S, McGuire MH, Mangala LS, Lee S, Stur E, Hu W, Bayraktar E, Villar-Prados A, Ivan C, Wu SY, Yokoi A, Dasari SK, Jennings NB, Liu J, Lopez-Berestein G, Ram P, Sood AKCell reportsGain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021 02 09; 34(6):108726.Cell Rep2021-02-09T00:00:002021Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.Authorship 10267451034348992McGuire MH, Dasari SK, Yao H, Wen Y, Mangala LS, Bayraktar E, Ma W, Ivan C, Shoshan E, Wu SY, Jonasch E, Bar-Eli M, Wang J, Baggerly KA, Sood AKMolecular cancer research : MCRGene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.Mol Cancer Res2021-08-04T00:00:002021Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling.Authorship 10279691134407412Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AKCell reportsCD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.Cell Rep2021-08-17T00:00:002021CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.Authorship 1059263436077735Stur E, Bayraktar E, Dal Molin GZ, Wu SY, Mangala LS, Yao H, Wang Y, Ram PT, Corvigno S, Chen H, Liang H, Tworoger SS, Levine DA, Lutgendorf SK, Liu J, Moore KN, Baggerly KA, Karlan BY, Sood AKCancersMolecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. Cancers (Basel). 2022 Aug 30; 14(17).Cancers (Basel)2022-08-30T00:00:002022Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma.Authorship 10804061737781339Chen R, Coleborn E, Bhavsar C, Wang Y, Alim L, Wilkinson AN, Tran MA, Irgam G, Atluri S, Wong K, Shim JJ, Adityan S, Lee JS, Overwijk WW, Steptoe R, Yang D, Wu SYMolecular therapy oncolyticsmiR-146a inhibits ovarian tumor growth in?vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T?cell infiltration. Mol Ther Oncolytics. 2023 Dec 19; 31:100725.Mol Ther Oncolytics2023-09-13T00:00:002023miR-146a inhibits ovarian tumor growth in?vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T?cell infiltration.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1InstructorInstructortrue1InstructorInstructor